KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accumulated Expenses (2018 - 2025)

Esperion Therapeutics' Accumulated Expenses history spans 8 years, with the latest figure at $11.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 6.27% year-over-year to $11.9 million; the TTM value through Dec 2025 reached $11.9 million, down 6.27%, while the annual FY2025 figure was $11.9 million, 6.27% down from the prior year.
  • Accumulated Expenses reached $11.9 million in Q4 2025 per ESPR's latest filing, down from $18.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $34.5 million in Q3 2021 to a low of $3.4 million in Q2 2024.
  • Average Accumulated Expenses over 5 years is $12.1 million, with a median of $8.4 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: plummeted 81.57% in 2023, then surged 425.69% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $7.0 million in 2021, then fell by 22.63% to $5.4 million in 2022, then skyrocketed by 98.47% to $10.8 million in 2023, then increased by 18.29% to $12.7 million in 2024, then dropped by 6.27% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Accumulated Expenses are $11.9 million (Q4 2025), $18.6 million (Q3 2025), and $8.4 million (Q2 2025).